View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2020updated 03 Mar 2022 5:37am

Abbott secures CE Mark for mitral valve repair device

Abbott has received CE Mark for fourth-generation MitraClip Transcatheter Mitral Valve Repair System, its latest minimally invasive mitral valve repair device.

Abbott has received CE Mark for fourth-generation MitraClip Transcatheter Mitral Valve Repair System, its latest minimally invasive mitral valve repair device.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Called MitraClip G4, the device is now approved as a non-surgical option to treat mitral regurgitation (MR) in Europe and other countries that recognise CE Mark. The device is already cleared for use in the US.

The MitraClip G4 system features enhanced clip-based technology, which builds on the MitraClip’s proven delivery system.

It is designed to provide physicians with advanced steering during implantation. Furthermore, the new delivery system has four clip sizes, including two wider clips, offering a variety of treatment options to suit patients’ individual mitral valve anatomy.

The new device also provides independently controlled grippers that will enable physicians to grasp one or both mitral valve leaflets at a time during the MitraClip procedure, if necessary.

Abbott structural heart business senior vice-president Michael Dale said: “An enduring measure of our mission to help people live better lives through better health is our success in advancing new standards of care for the treatment of structural heart diseases.

“This CE Mark, along with other recent approvals and advancements for our MitraClip device, underscores the need for MitraClip’s innovative therapy – which has become a preferred choice for the treatment of mitral regurgitation around the world.”

MR is a common heart condition that affects one in ten adults above the age of 75.

Patients suffering from this progressive condition have a mitral valve that does not close fully, allowing blood to flow backward into the left atrium of the heart instead of flowing forward and to the rest of the body.

Typically, open-heart surgery is considered as the preferred treatment method for MR. However, it is not applicable to all patients due to the potential risk of complications, stemming from comorbidities, advanced age or other issues.

MitraClip is considered to be the first-of-its-kind minimally invasive transcatheter mitral valve repair (TMVr) therapy that can be a life-saving treatment option for select patients with primary or secondary MR.

It is delivered to the heart through a vein in the leg. It reduces the backflow of blood by clipping together portions of the leaflets, or flaps, of the mitral valve.

Once in place, the device restores the normal functioning of the mitral valve and the heart’s ability to pump oxygenated blood.

The company noted that MitraClip has over 16 years of clinical experience with proven safety, survival and durable clinical outcomes.

The clinical study of more than 1,000 MitraClip patients found 99% implant success rate. It also demonstrated MR reduction to the level of none or trace in patients with either primary MR or secondary MR at 30 days.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network